Advanced Biomed Inc. (ADVB) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2026, filed Oct 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ADVB SEC filings page.
Advanced Biomed Inc. (ADVB) reported $128K in revenue for fiscal year 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The latest figures show a development-stage business with reported profit disconnected from operations, while its balance sheet became less liability-funded.
In FY2026, net income was$6.7M while operating cash flow was-$1.9M , an unusual gap between accounting results and cash generation. That sits alongside an operating loss of$6.2M , indicating the reported profit appears to have come from non-operating items rather than the core business producing cash.
Debt-to-equity fell from 5.6x in FY2025 to 0.1x in FY2026, indicating the balance sheet became far less liability-funded. Current ratio rose from 1.2x to 9.3x over the same period, pointing to much greater short-term coverage.
FY2026 revenue was only
Financial Health Signals
Advanced Biomed Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Advanced Biomed Inc. scores 1.78, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($8.5M) relative to total liabilities ($1.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Advanced Biomed Inc. passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.
For every $1 of reported earnings, Advanced Biomed Inc. used $0.29 of operating cash (-$1.9M OCF vs $6.7M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Advanced Biomed Inc. reported an operating loss of $6.2M against $7K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Advanced Biomed Inc. earned $0.12 per diluted share (EPS) in Q4 2026. Against the prior quarter it is up 131.6%.
Not reported for Q4 2026.
Not reported for Q4 2026.
Not reported for Q4 2026.
Cash & Balance Sheet
Advanced Biomed Inc. held $386K in cash as of Q4 2026; long-term debt is not reported for that period.
Not reported for Q4 2026.
Not reported for Q4 2026.
Margins & Returns
None of these metrics is reported for Q4 2026.
Capital Allocation
None of these metrics is reported for Q4 2026.
ADVB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $243K+10.6% | $186K-12.3% | $236K+29.9% | N/A | $220K-29.8% | $212K+12.7% | $182K |
| SG&A Expenses | N/A | $277K-20.4% | $210K+210.8% | $288K-14.9% | N/A | $348K-19.5% | $68K-85.4% | $338K |
| Interest Expense | N/A | $112 | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$489K+64.7% | $6.9M+855.4% | -$387K-45.7% | N/A | -$1.4M-31.0% | -$908K-524.7% | -$266K |
| EPS (Basic) | $0.12+500.0% | -$0.38+71.9% | $0.31+720.0% | -$0.02-100.0% | -$0.03+25.0% | -$1.35-2600.0% | -$0.05-400.0% | -$0.01 |
| EPS (Diluted) | $0.12 | -$0.38 | $0.31+720.0% | -$0.02 | -$0.03+25.0% | -$1.35 | -$0.05-400.0% | -$0.01 |
| Diluted Shares (Avg) | N/A | 1M | 22M+8.2% | 22M | N/A | 1M | 20M0.0% | 20M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Operating Income, EBITDA, Income Tax.
ADVB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $13.8M-39.9% | $10.6M+28.5% | $10.9M+140.9% | $6.2M | $22.9M+412.6% | $8.3M | $4.5M | N/A |
| Current Assets | $13.7M-38.6% | $10.5M+36.2% | $10.7M+241.9% | $5.8M | $22.4M+633.6% | $7.7M | $3.1M | N/A |
| Cash & Equivalents | $386K+1138.1% | $2.6M-18.1% | $2.6M-1.6% | $2.7M+0.4% | $31K-98.8% | $3.2M+19.2% | $2.6M-4.6% | $2.6M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.5M-92.4% | $1.4M-65.4% | $1.4M-64.8% | $3.2M | $19.4M+593.0% | $4.2M | $3.9M | N/A |
| Current Liabilities | $1.5M-92.3% | $1.4M-65.3% | $1.3M-67.3% | $3.0M | $19.2M+604.1% | $4.1M | $3.8M | N/A |
| Non-Current Liabilities | $0-100.0% | $11K-75.5% | $115K+105.0% | $194K | $146K+125.7% | $44K | $56K | N/A |
| Total Equity | $12.3M+253.0% | $9.2M+123.0% | $9.5M+1431.7% | $3.0M+174.6% | $3.5M+109.1% | $4.1M+929.6% | $619K+214.5% | $1.1M |
| Retained Earnings | -$12.6M+34.7% | -$13.3M+28.5% | -$12.8M+25.6% | -$19.6M | -$19.2M-20.4% | -$18.5M | -$17.1M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ADVB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$583K+62.2% | -$240K+93.0% | -$514K+39.0% | -$610K-1956.4% | -$1.5M-224.5% | -$3.4M-219.9% | -$842K | -$30K |
| Depreciation & Amortization | N/A | $9K-82.3% | $14K-74.0% | $48K-53.0% | $276K+79.2% | $53K-36.5% | $56K-38.0% | $102K |
| Capital Expenditures | N/A | $1K-42.9% | $13K+20.7% | $2K-91.1% | $20K-62.2% | $2K-91.7% | -$11K | $20K |
| Free Cash Flow | N/A | -$241K+92.9% | -$526K+38.2% | -$612K-1132.7% | -$1.6M-195.6% | -$3.4M-212.3% | -$853K | -$50K |
| Investing Cash Flow | -$2.5M-12258.7% | -$1K+42.9% | -$13K-220.7% | -$2K+91.1% | -$20K+62.2% | -$2K-108.3% | $11K | -$20K |
| Financing Cash Flow | $937K+222.4% | $268K-95.5% | $315K-22.7% | $447K+14.0% | -$765K-336.6% | $5.9M+949.3% | $408K | $393K |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
ADVB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | -5.3%+28.2pp | 72.3%+219.0pp | -12.9%+11.4pp | N/A | -33.5% | -146.7%-72.8pp | -24.3% |
| Return on Assets | N/A | -4.6%+12.1pp | 63.2%+83.4pp | -6.2% | N/A | -16.7% | -20.2% | N/A |
| Current Ratio | 9.33+8.2x | 7.38+5.5x | 8.56+7.7x | 1.92 | 1.160.0x | 1.88 | 0.82 | N/A |
| Debt-to-Equity | 0.12-5.5x | 0.16-0.9x | 0.14-6.1x | 1.08 | 5.57+3.9x | 1.01 | 6.28 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Advanced Biomed Inc. ADVB | FY2026 | $128K | $6.7M | N/A | $8.5M | — |
| iSpecimen Inc. ISPC | FY2025 | $1.9M | -$10.5M | N/A | $2.8M | 30/100 |
| bioAffinity Technologies, Inc. BIAF | FY2025 | $6.2M | -$14.9M | N/A | $2.8M | 45/100 |
| Mainz Biomed N.V. MYNZ | FY2025 | $537K | -$16.2M | N/A | $10.6M | — |
| XWELL, Inc. XWEL | FY2025 | $29.2M | -$17.0M | -58.2% | $8.2M | 28/100 |
| PROPHASE LABS INC PRPH | FY2025 | $4.3M | -$14.7M | N/A | $1.5M | — |
Where Advanced Biomed Inc. Ranks
Frequently Asked Questions
What is Advanced Biomed Inc.'s annual revenue?
Advanced Biomed Inc. (ADVB) reported $128K in total revenue for fiscal year 2026. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Advanced Biomed Inc. profitable?
Yes, Advanced Biomed Inc. (ADVB) reported a net income of $6.7M in fiscal year 2026.
What is Advanced Biomed Inc.'s return on equity (ROE)?
Advanced Biomed Inc. (ADVB) has a return on equity of 54.4% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Advanced Biomed Inc.'s operating cash flow?
Advanced Biomed Inc. (ADVB) recorded an outflow of $1.9M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are Advanced Biomed Inc.'s total assets?
Advanced Biomed Inc. (ADVB) had $13.8M in total assets as of fiscal year 2026, including both current and long-term assets.
What is Advanced Biomed Inc.'s current ratio?
Advanced Biomed Inc. (ADVB) had a current ratio of 9.33 as of fiscal year 2026, which is generally considered healthy.
What is Advanced Biomed Inc.'s debt-to-equity ratio?
Advanced Biomed Inc. (ADVB) had a debt-to-equity ratio of 0.12 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Advanced Biomed Inc.'s return on assets (ROA)?
Advanced Biomed Inc. (ADVB) had a return on assets of 48.6% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Advanced Biomed Inc.'s P/E ratio?
Advanced Biomed Inc. (ADVB) trades at 1.3x earnings, its market capitalization divided by net income of $6.7M net income, FY2026. The market capitalization is $8.5M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Advanced Biomed Inc.'s price-to-sales ratio?
Advanced Biomed Inc. (ADVB) trades at 66.8x sales, its market capitalization divided by revenue of $128K revenue, FY2026. The market capitalization is $8.5M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Advanced Biomed Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, Advanced Biomed Inc. (ADVB) held $386K in cash, cash equivalents and investments, and reported an operating cash outflow of $1.9M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Advanced Biomed Inc.'s Altman Z-Score?
Advanced Biomed Inc. (ADVB) has an Altman Z-Score of 1.78, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Advanced Biomed Inc.'s Piotroski F-Score?
Advanced Biomed Inc. (ADVB) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Advanced Biomed Inc.'s earnings high quality?
For every $1 of reported earnings, Advanced Biomed Inc. (ADVB) used $0.29 of operating cash (-$1.9M OCF vs $6.7M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Advanced Biomed Inc. cover its interest payments?
Advanced Biomed Inc. (ADVB) reported an operating loss of $6.2M against $7K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.